Daidzein supplementation decreases serum triglyceride and uric acid concentrations in hypercholesterolemic adults with the effect on triglycerides being greater in those with the GA compared with the GG genotype of ESR-β RsaI.

Study answer

What this study found

Daidzein supplementation for 6 months reduced triglycerides and uric acid, with no meaningful dose-response difference between 40 mg/day and 80 mg/day. Compared with placebo, triglycerides decreased significantly in both the DAI40 and DAI80 groups (P < 0.05), and there was no significant difference between the two daidzein doses. In hypertriglyceridemic participants, triglycerides fell by 0.62 ± 0.71 mmol/L (n = 27) in DAI40 and 0.69 ± 0.71 mmol/L (n = 21) in DAI80 versus placebo (n = 22; P < 0.05). Uric acid reductions were greater in the DAI80 group than placebo (P < 0.05), while total…

Study & population

Six-month intervention in hypercholesterolemic adults aged 40 to 65 years recruited in Chongqing, China.

Intervention

Participants in the active arms received 5 g/day soy isolated protein supplemented with daidzein, taken orally as a powder mixed with water, milk, or porridge for 6 months.

Key limitation

The trial was limited to hypercholesterolemic adults from a single city in China, which reduces generalizability.

View full study detailsView sourceOpen PDF

Original abstract